William Park

Mr. William Park

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in Viruses
Verified
Journal Article
Open access
PDF file
XZXiaoan Zhang
Xiaoan Zhang
WPWilliam Park
William Park
MTMarijn Thijssen
Marijn Thijssen
YXYanjuan Xu
Yanjuan Xu
LTLong Ping Victor Tse
Long Ping Victor Tse
XFXiaofeng Fan
Xiaofeng Fan
Anellovirus (AV) is a ubiquitous virus in the human population. Individuals can be infected with multiple AV genera and species to form a heterogeneous repertoire, termed the anellome. Using advanced methods, we examined the anellomes from 12 paired serum and liver samples, as well as 2701 subjects with different clinical diagnoses. Overall, anellomes are remarkably individualized, with significant among-group differences (Kruskal–Wallis test p = 6.6 × 10−162 for richness and p = 7.48 × 10−162 for Shannon entropy). High dissimilarity scores (beta diversity) were observed between patient groups, except for paired serum and liver samples. At the population level, the relative abundance of combinational AV genus Betatorquevirus (torque teno mini viruses, TTMV), and Gammatorquevirus (torque teno midi viruses, TTMDV) exhibited an exponential distribution with a low bound point at 32%. Defined by this value, the AV TTMV/TTMDV-expanded anellome was significantly enriched among patients with acute liver failure (31.7%) and liver transplantation (40.7%), compared with other patient groups (χ2 test: p = 4.1 × 10−8–3.2 × 10−3). Therefore, anellome heterogeneity may be predictive of clinical outcomes in certain diseases, such as liver disease. The consistency of anellome between paired serum and liver samples indicates that a liquid biopsy approach would be suitable for longitudinal studies to clarify the causality of the AV TTMV/TTMDV-expanded anellome in the outcomes of liver disease.

16 September 2024 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
WPWilliam Park
William Park
TCTimothy Chrusciel
Timothy Chrusciel
DVDivya R. Verma
Divya R. Verma
MBMina M Benjamin
Mina M Benjamin
For most patients with hypertrophic cardiomyopathy (HCM), the clinical course is considered relatively benign, similar to hypertensive heart disease (HHD). We compared the long-term outcomes in patients with HCM versus HHD from a large healthcare system database. Data from SSM Virtual Data Warehouse were used to identify patients with a new diagnosis of either HCM or HHD who followed up in our system for at least 6 months. HCM patients were matched 1:1 to HHD patients based on age, sex, and race. Outcomes examined included heart failure (HF) admission, ventricular tachyarrhythmia (ventricular fibrillation or sustained ventricular tachycardia), and need for pacemaker or defibrillator implantation. We identified 1904 HCM patients along with HHD controls. After adjusting for demographic characteristics and relevant comorbidities, HCM had higher odds of HF admission (odds ratio [OR]: 1.73, 95% confidence interval [CI]: 1.43–2.10), ventricular tachyarrhythmias (OR: 2.31, CI: 1.60–3.33), pacemaker implantation (OR: 2.14, CI: 1.29–3.57), and defibrillator implantation (OR: 3.77, CI: 1.82–7.83). Survival analysis confirmed the difference in outcomes early on from the time of diagnosis. In this retrospective study from a large healthcare system database, HCM patients had significantly higher incidences of HF admission, ventricular tachyarrhythmias, and pacemaker or defibrillator implantation compared to HHD patients.